Japanese pharmaceutical giant Astellas Pharma has announced the acquisition of US-based Potenza Therapeutics in a significant transaction valued at up to $404.7 million. This strategic move is the culmination of a collaborative partnership established between the two companies in 2015, aimed at advancing novel immuno-oncology (IO) therapies. Under the terms of the acquisition, Astellas has […]
Brooklyn Immuno Therapeutics, a New York-based clinical-stage biopharmaceutical company specializing in cytokine-based cancer therapies, has announced the acquisition of IRX Therapeutics’ assets. The terms of the deal were not disclosed. Brooklyn Immuno Therapeutics, a company focused on developing innovative treatments for cancer, has expanded its portfolio by acquiring IRX Therapeutics. This acquisition positions Brooklyn Immuno […]
Nordic Nanovector has commenced the dosing of the first patient in its Phase 1b clinical trial, dubbed Archer-1, which aims to evaluate the combination of its investigational lymphoma drug Betalutin (177Lu-satetraxetan-lilotomab) with Roche’s rituximab (RTX) as a second-line treatment for follicular lymphoma (2L FL). This trial is a critical step in exploring novel treatments for […]
Irish biopharmaceutical company Alkermes has announced an expansion of its ongoing Phase 1 trial to evaluate the safety and anti-tumor activity of its immuno-oncology drug ALKS 4230 in combination with Merck’s PD-1 inhibitor KEYTRUDA (pembrolizumab). This trial aims to explore the potential of this combination therapy in treating advanced solid tumors. ALKS 4230 is an […]
Roche, the Swiss pharmaceutical giant, has announced its plans to fully acquire Flatiron Health, a leading oncology software company, for $1.9 billion. This strategic move aims to fast-track the development of cancer treatments by leveraging Flatiron Health’s advanced data analytics and electronic health records software. Strategic Expansion in Oncology The acquisition marks a significant step […]
Lilly’s breast cancer drug, abemaciclib given in combination with fulvestrant has met its primary endpoint of progression-free survival (PFS) in a phase 3 breast cancer trial.
Indianapolis-based pharmaceutical giant Lilly has announced positive outcomes from its phase 3 clinical trial, MONARCH 2, involving its innovative breast cancer treatment, abemaciclib, in combination with fulvestrant. This trial marks a significant advancement in the treatment of hormone-receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer. Groundbreaking Results in Cancer Treatment The […]
Texas-based biopharmaceutical company Genprex has unveiled positive interim data from an ongoing phase II clinical trial, NCT01455389, for its lung cancer drug candidate, Oncoprex. Conducted at The University of Texas MD Anderson Cancer Center, the trial focuses on the investigational immunogene therapy drug in combination with the tyrosine kinase inhibitor erlotinib (Tarceva), targeting patients with […]